Will Adjuvant Pembrolizumab Be an Effective Therapy for High-Risk Melanoma?
June 4th 2019Investigators are now enrolling patients for a phase III trial, KEYNOTE-716, to assess the efficacy and safety of adjuvant pembrolizumab in adult and pediatric patients with surgically resected high-risk stage II melanoma.
ILLUMINATE 301 Will Study Experimental Immunotherapy for Patients With Advanced Melanoma
June 4th 2019Investigators are now enrolling for a phase III trial testing the experimental immunotherapy tilsotolimod plus ipilimumab in patients with advanced melanoma who have progressed on anti–PD-1 therapy.